Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease
作者:Michael O. Clarke、Xiaowu Chen、Aesop Cho、William E. Delaney、Edward Doerffler、Maria Fardis、Mingzhe Ji、Michael Mertzman、Rowchanak Pakdaman、Hyun-Jun Pyun、Tanisha Rowe、Cheng Y. Yang、X. Christopher Sheng、Choung U. Kim
DOI:10.1016/j.bmcl.2011.04.125
日期:2011.6
discovered by employing a phosphinicacid as a carboxylate isostere. The replicon activity and pharmacokinetic profile of this series of compounds was optimized by exploring the substitution of the phosphinicacid, as well as conformationally constraining these compounds through macrocyclization. The syntheses and preliminary biological evaluation of these phosphinicacids is described.
This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
这项发明涉及用于治疗丙型肝炎病毒感染的治疗分子组合。本发明涉及方法、用途、给药方案和组合物。
Antiviral phosphinate compounds
申请人:Casarez Anthony
公开号:US08674088B2
公开(公告)日:2014-03-18
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.